Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.

Patients with B-cell chronic lymphocytic leukemia (B-CLL) segregate into subgroups with very different survival times. Because clinical observations suggest that leukemic cells accumulate at different rates, we measured telomere length and telomerase activity in B-CLL cells to distinguish differences in cellular replication. Our data indicate that the telomeres of B-CLL cells are shorter than telomeres of B cells from healthy subjects, indicating that the leukemic cells have a prolonged proliferative history. Leukemic cells of the immunoglobulin V gene mutation subgroups differ in telomere length and telomerase activity. B lymphocytes from the subgroup with poor outcome and with limited IgV gene mutations have uniformly shorter telomeres and more telomerase activity than those from the subgroup with better outcome and with considerable mutations. Differences in telomere length appear to largely reflect the proliferative histories of precursors of the leukemic cells, although differences in cell division, masked by the action of telomerase, cannot be excluded. These results may provide insight into the stages of maturation and the activation pathways of the cells that give rise to B-CLL. In addition, they reinforce the concept that B-CLL is not simply an accumulative disease of slowly dividing B lymphocytes but possibly one of B cells with extensive proliferative histories.

[1]  N. Chiorazzi,et al.  B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. , 2003, Annual review of immunology.

[2]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[3]  R. Rosenquist,et al.  Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications , 2003, British Journal of Cancer.

[4]  K. Toellner,et al.  Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens , 2003, European journal of immunology.

[5]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[6]  Douglas A. Hosack,et al.  Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia. , 2002, Leukemia research.

[7]  Xiao-Jie Yan,et al.  B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. , 2002, Blood.

[8]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[9]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[10]  G. Roos,et al.  Telomerase regulation and telomere dynamics in germinal centers , 2001, European journal of haematology.

[11]  R. Hodes,et al.  Lineage-Specific Telomere Shortening and Unaltered Capacity for Telomerase Expression in Human T and B Lymphocytes with Age , 2000, The Journal of Immunology.

[12]  E. Cesarman,et al.  Telomerase activity in B‐cell non‐Hodgkin lymphoma , 2000, Cancer.

[13]  M. Robinson,et al.  Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. , 1999, Genes & development.

[14]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[15]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[16]  R. Reddel,et al.  Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. , 1999, Cancer research.

[17]  L. Chieco‐Bianchi,et al.  Telomerase activity in chronic lymphoproliferative disorders of B‐cell lineage , 1999, British journal of haematology.

[18]  R. Hodes Telomere Length, Aging, and Somatic Cell Turnover , 1999, The Journal of experimental medicine.

[19]  W. Hilbe,et al.  Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. , 1998, Cancer research.

[20]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[21]  T. Suzuki,et al.  Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. , 1998, Biochemical and biophysical research communications.

[22]  A. Cimmino,et al.  In vivo telomere dynamics of human hematopoietic stem cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Reddel,et al.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines , 1997, Nature Medicine.

[24]  V. Reuter,et al.  Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  R. Hodes,et al.  Telomere lengthening and telomerase activation during human B cell differentiation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Insel,et al.  Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. , 1997, Journal of immunology.

[27]  Nam W. Kim,et al.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP) , 1997, Nucleic Acids Res..

[28]  H. Igarashi,et al.  Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. , 1997, Blood.

[29]  P. Gregersen,et al.  Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. , 1997, Journal of immunology.

[30]  T. Kipps,et al.  What is the CLL B-lymphocyte? , 1996, Leukemia & lymphoma.

[31]  C. Harley,et al.  In situ analysis of changes in telomere size during replicative aging and cell transformation , 1996, The Journal of cell biology.

[32]  D. Broccoli,et al.  Telomerase activity in normal and malignant hematopoietic cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Reddel,et al.  Telomere elongation in immortal human cells without detectable telomerase activity. , 1995, The EMBO journal.

[34]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[35]  G. Roos,et al.  Telomerase activity in vivo in human malignant hematopoietic cells. , 1994, Oncogene.

[36]  J. Murnane,et al.  Telomere dynamics in an immortal human cell line. , 1994, The EMBO journal.

[37]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[38]  G. Dighiero,et al.  The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. , 1994, Immunology today.

[39]  E. Kabat,et al.  Reaction of germinal centers in the T-cell-independent response to the bacterial polysaccharide alpha(1-->6)dextran. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. H. Berg,et al.  Peptide nucleic acids and their potential applications in biotechnology. , 1993, Trends in biotechnology.

[41]  R. Wellinger,et al.  Use of non-denaturing Southern hybridization and two dimensional agarose gels to detect putative intermediates in telomere replication inSaccharomyces cerevisiae , 1992, Chromosoma.

[42]  C B Harley,et al.  Telomere loss: mitotic clock or genetic time bomb? , 1991, Mutation research.

[43]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[44]  M. Zelen,et al.  Studies of leukocyte kinetics by liquid scintillation counting in normal individuals and in patients with chronic myelocytic leukemia. , 1966, The Journal of clinical investigation.

[45]  L. Hayflick THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.

[46]  P. Gregersen,et al.  Simultaneous flow cytometric analysis of cell surface markers and telomere length: analysis of human tonsilar B cells. , 2001, Journal of immunological methods.

[47]  P. Gregersen,et al.  Chronic lymphocytic leukemia: a proliferation of B cells at two distinct stages of differentiation. , 2000, Current topics in microbiology and immunology.

[48]  Terry J. Hamblin,et al.  Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia , 1999 .

[49]  J. Jurlander The cellular biology of B-cell chronic lymphocytic leukemia. , 1998, Critical reviews in oncology/hematology.

[50]  P. Lansdorp,et al.  Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry , 1998, Nature Biotechnology.

[51]  A. Novarino,et al.  The nature of the B lymphocyte in B-chronic lymphocytic leukemia. , 1993, Blood cells.

[52]  Z. Desai,et al.  The proliferative activity of B-chronic lymphocytic leukaemia lymphocytes prior to and after stimulation with TPA and PHA. , 1991, Leukemia research.

[53]  E. Blackburn,et al.  Recognition and elongation of telomeres by telomerase. , 1989, Genome.